Good morning, everyone. My name is Jamie, and I will be your operator today. At this time, I would like to welcome you to Imunon's Second Quarter 2020 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. Following the speaker's prepared remarks, there will be a question-and-answer session. You may press star and then one on your touchtone telephones to ask a question at that time. Please keep in mind if you are using a speakerphone, you must release your mute function to allow the signal to reach our equipment. Again, that is star and then one to ask a question during the question-and-answer session. Please also note today's event is being recorded. At this time, I'd like to turn the floor over to Kim Golodetz. Please go ahead. Thank you, and good morning, everyone. This is Kim Golodetz with LHA. Welcome to Imunon's Second Quarter 2024 financial results and business update conference call. During today's call, management will be making forward-looking statements regarding Imunon's expectations and projections about future events. In general, forward-looking statements can be identified by words such as expects, anticipates, believes, or other similar expressions. These statements are based on current expectations and are subject to a number of risks and uncertainties, including those set forth in the company's periodic filings with the Securities and Exchange Commission. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. I also caution that the content of this conference call is accurate only as of the date of the live broadcast, August 14th, 2024. Imunon undertakes no obligation to revise or update comments made during this call, except as required by law. With that said, I would like to turn the call over to Michael Tardugno, Imunon's Executive Chairman. Michael? Thank you, Kim, and good morning, everyone. I just wanted to take the liberty to say a few words before turning the call over to Stacy Lindborg, our President and Chief Executive Officer, and to David Guerrero, who is our interim Chief Financial Officer, as we seek a permanent replacement for our retired CFO, Jeff Church. And just a point, following our prepared remarks, there will be time for questions, and this is your opportunity. We encourage you to, if you have a question, to use this time to ask us. We're happy to respond to your questions and concerns. On the fundamentals, I can report that your company is sound. The second quarter and recent weeks give testament to that and to Dr. Lindborg's strategy and leadership. As you know, we recently reported long-awaited top-line data from our phase II study of IMNN-001, our unique IL-12 candidate in ovarian cancer. These are women with very few options, facing a standard of care that has seen very little change over the past 25 years. Given that, I can report that the results from our study, in a word, outstanding. Unequivocally outstanding. In support of this remarkable outcome, Stacy has streamlined the company, refocused its attention, reduced expenses, and despite the challenging comparable deal terms that we've seen recently, closed on a truly investor-friendly financing in this tough, tough capital market. I am delighted with our company's progress over the past quarters I hope you are, and with the future promise that IMNN-001 has for ovarian cancer patients. I'll also remind you that, during the second quarter, Dr. Lindborg was appointed President, Chief Executive of Imunon. I'm sure that it was a difficult decision for her, as she left a similar position with a company that she very, very much believed in, to lead the development of our lead asset, IMNN-001, and to shape the company's strategy. I trust that you will agree with me that she has hit the ground running. So now it's my pleasure to turn the call over to Stacy. Thank you, Michael. As Michael's indicated, it has been an exciting and fulfilling time over the last few months at Imunon, as the promise of our science comes closer to making a real difference in the lives of patients. I'm further emboldened by the talent and dedication I see in the community of treating physicians and in the Imunon team. Let me assure you, we are ready for Imunon's next chapter. We're motivated and honored by the role that we get to play in advancing the treatment of women with ovarian cancer. Just a short time ago, a couple of weeks, we reported top-line data from our OVATION 2 Study. As you know, a phase II trial in ovarian cancer, and we may have in our hands the first and only immunotherapy that is effective for the treatment of ovarian cancer. This is a terrible cancer that in the U.S. alone, leads to more than 20,000 new diagnoses and about 13,000 deaths every year, with more than 250,000 women diagnosed with the disease globally each year. I'll take just a moment to briefly review the trial before addressing our plans. IMNN-001 is a DNA-mediated IL-12 immunotherapy being evaluated for the localized treatment of advanced ovarian cancer. OVATION 2 is an open-label, well-controlled, randomized study of 112 patients evaluating the dosing, safety, efficacy, and biological activity of intraperitoneal administration of IMNN-001 in combination with neoadjuvant chemotherapy, or NACT, as we often refer to it. We're studying treatment-naïve patients newly diagnosed with the disease, including epithelial ovarian, fallopian tube, or primary peritoneal cancers. The trial design compares NACT plus IMNN-001, administered weekly, versus standard of care NACT alone. Patients randomized to the IMNN-001 treatment arm received up to 17 doses of 100 mg/m² of our drug in combination and in addition to NACT. So now to the extraordinary findings, which we have, which have relevance to our contemplated phase III pivotal trial, including the following: an 11.1-month improvement in overall survival with IMNN-001 in the intent-to-treat population, with a hazard ratio translating to a 35% improvement in overall survival. This is, by all standards or measures, a clinically meaningful improvement in a difficult-to-treat disease. For the 90% of patients receiving 3 or more of the 17 specified doses, median overall survival was improved by close to 16 months. This is consistent with the dose-dependent signal that was clearly demonstrated in OVATION 1. Furthermore, we saw potential for a remarkable improvement in overall survival benefit with IMNN-001 in patients exposed to standard of care PARP inhibitor therapy, and this was in 38% of the intent-to-treat population. For this group, the hazard ratio dropped to 0.41, and the median overall survival in the IMNN-001 treatment arm had not yet been reached at the time of the data lock, which compares with the median overall survival of 37.1 months in the standard of care treatment arm. Regarding our next steps, we have taken a number of steps to conserve capital and align our critical needs with available funds. We are within days of requesting an end-of-phase II meeting with the FDA to validate our conclusions and clarify our path for the registration study ahead. This means we can expect an end-of-phase II meeting this fall with the FDA this fall, and this will permit us to begin our phase III ovarian cancer study in the first quarter of 2025. The pace of the study will depend on several factors, including access to capital and patient recruitment. But at this point, we are targeting top-line data readout at the end of 2028. As you know, OVATION 2 is not the only study with IMNN-001 in ovarian cancer. We have an ongoing study, principally funded by the Break Through Cancer Foundation, that is proceeding at The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center, under the leadership of study PI, Dr. Amir Jazaeri. The study is evaluating IMNN-001 on minimal residual disease, or MRD, as determined by second-look laparoscopy when administered in combination with bioequivalent Avastin and NACT. Subjects newly diagnosed with ovarian cancer, fallopian tube, or primary peritoneal cancer will be included, and to date, seven patients have been enrolled and received treatment. As the first few patients have reached the primary endpoint, Dr. Jazaeri will now conduct a pilot study to test circulating tumor DNA levels following treatment using a next-generation ctDNA assay. We look forward to sharing insights with you from this data and harnessing insights from this data for OVATION 3. Switching now to the proof of concept phase I study of our DNA vaccine candidate for COVID-19. During the second quarter, we began patient enrollment with IMNN-101 as a seasonal COVID-19 booster vaccine, and we believe that the preclinical efficacy we've generated, along with the superior handling logistics, which we've discussed on past calls, will make this vaccine attractive to a pharma partner. Our plan is to complete phase I report data by the end of the year, and at that point, we will actively seek a partner to continue development. Now I'll turn the call over to Dave Guerrero, our interim CFO, for a discussion of our quarterly financial results. Dave? Thank you, Stacy. Details of Imunon's second quarter 2024 financial results are included in the press release we issued this morning and in our Form 10-Q, which we filed today before the market opened. As of June 30, 2024, Imunon had $5.3 million in cash investments and accrued interest receivable. Subsequent to the close of the quarter, we received net proceeds of approximately $9 million from a registered direct offering. We will continue to focus on strong cash management, and as Stacy indicated, we have taken steps to evaluate and prioritize our spending and expect our cash runway to extend into the third quarter of 2025. Imunon reported a net loss for the second quarter of 2024 of $4.8 million, or $0.51 per share, compared with a net loss of $5.6 million, or $0.61 per share, for the second quarter of 2023. Operating expenses were $5 million for the second quarter of 2024, a decrease of $500,000 or 8% from the second quarter of 2023. R&D expenses were $2.8 million in the second quarter of 2024, compared with $3.1 million in the same period of 2023. CMC costs decreased to $500,000, compared with $700,000 a year ago. The lower CMC costs were primarily due to the establishment of internal capability to produce plasmid DNA. Costs associated with our PlaCCine program decreased by $200,000 in the second quarter of 2024 compared to the second quarter of 2023. These decreases were partially offset by a $200,000 increase in regulatory and other clinical costs in the second quarter of 2024 compared to the second quarter of 2023. General and administrative expenses were $2.2 million in the second quarter of 2024, compared with $2.3 million in the same period of 2023. The decrease was primarily attributable to lower non-cash stock compensation expense of $100,000 and employee-related expenses of $100,000, partially offset by an increase in legal fees of $100,000. Other non-operating income was $200,000 in the second quarter of 2024, compared with other non-operating expense of $100,000 in the same period of 2023. The company incurred a loss on extinguishment of debt of $300,000 on its loan facility with Silicon Valley Bank in the second quarter of 2023, upon the repayment in full of this loan facility. Turning briefly to the financial results for the first half of 2024. The company reported a net loss of $9.7 million, or $1.03 per share in the first half of 2024, compared with a net loss of $11.2 million, or $1.28 per share for the first half of 2023. R&D expenses were $6.1 million in the first half of 2024, compared with $5.8 million in the same period of 2023. Costs associated with the PlaCCine program increased to $2.8 million in the first half of 2024, compared to $2.3 million in the first half of 2023. Regulatory and other clinical costs increased to $1.1 million in the first half of 2024, compared to $700,000 in the first half of 2023. These increases were partially offset by a $600,000 decrease in CMC costs in the first half of 2024, compared to the same period of 2023. General and administrative expenses were $3.9 million in the first half of 2024, compared with $5.4 million in the same period of 2023. The decrease was primarily attributable to lower non-cash stock compensation expense of $400,000, legal expenses of $400,000, employee-related expenses of $300,000, and insurance expense of $100,000. Other non-operating income was $300,000 in the first half of 2024, compared with $8,505 in the same period of 2023. The company incurred interest expense of $200,000, as well as $300,000 in debt extinguishment expense associated with its loan facility with Silicon Valley Bank in the first half of 2023. Investment income from the company's short-term investments decreased by $200,000 for the first half of 2024 from the same period in 2023 due to lower investment balances. With that financial review, I'll turn the call back to Stacy. Thank you, Dave, and thank you for so seamlessly stepping in following Jeff's retirement. It's been a very smooth transition. As Michael mentioned, we recently announced a financing with $10 million in gross proceeds under highly competitive terms. This was priced at $2 per share in an at-the-market deal that included 1 warrant for each share sold. The warrants have a stock price of $2. The additional capital added to our June balance brings our cash to approximately $14.5 million, which historically, this is well over 3.5 quarters of operating runway before consideration of further capital conservation initiatives and assures a bridge to important catalysts, which we can discuss. Following our discussions and with many premier healthcare investors, we have every confidence in our ability to access capital going forward, including the use of our ATM and possible interest from partners. I hope that you'll agree that the future of Imunon is bright, and that together with shareholders, we will deliver on our mission to have a meaningful impact on patients' lives. With that, I'd like to open up the call to your questions, operator? Ladies and gentlemen, at this time, we'll begin that question-and-answer session. To join the question queue, you may press star and then one. To withdraw your questions, you may press star and two. If you are using a speakerphone, we do ask that you please pick up the handset prior to pressing the numbers to ensure the best sound quality. Once again, that is star and then one to join the question queue. We'll pause momentarily to assemble the roster. Our first question today comes from Emily Bodnar from H.C. Wainwright. Please go ahead with your question. Hi, good morning. Thanks for taking the questions. Kind of a follow-up to some of the financing and funding discussions that you made. Could you maybe just talk about how you're thinking about strategy for financing a phase III study, given obviously those tend to be pretty large studies? Maybe if you can kind of comment on how extensive you think such a study could cost and, if you're potentially looking to raise additional capital or other strategies that you're evaluating, and potentially if you've gotten any partnership interest, since the OVATION 2 data came out? And then second, on the COVID booster, could you discuss the blinding for the phase I study, and if you're able to see the data as it kind of accrues? Thank you. Yeah, Emily, thank you for the question. Great to hear from you. Yeah, so I'll start with both questions, and then, Michael, I think you may want to add to it. So, you know, we're anticipating that this trial could cost on the order of $50 million. So, you know, adding $10 million to the balance sheet, and as we talked about with our cash runway, really takes us, takes us, very well into into 2025 actually, you know, well, well into the third quarter. Our goal, of course, this allows us to start the trial as we have planned. We're really intending with the way that we manage our company to continue to be able to achieve our core business objectives. This really is a bridge then for, and provides time for us to raise additional capital. And Michael, do you wanna offer additional? Sure. I mean, good question, Emily. It's always a challenge, particularly in recent days for microcap companies to raise capital, and you know that, and you probably cover a number of them. But I can say unequivocally that the quality of the investors that we spoke to during this financing roadshow were among the very best, and I think across the board, except maybe for a very small number. We spoke to a good number of quality investors. I think across the board, the reaction was overwhelmingly positive. Market conditions, among other things, may have limited their most recent interest, but I think that the story to tell from this financing roadshow is a little bit more time with the data. They'd like to see more maturity. I think that'll give us an opportunity to reengage and reengage successfully. In the meantime, the company is looking forward to some additional catalysts that may provide an opportunity either to use the ATM, engage strategic partners, or consider another equity round financing. On the whole, this has been the kind of history of many companies like ours, and I don't think honestly, from the data that we've seen and the impact on the lives of ovarian cancer patients, that this study will go without important financial support. Emily, you asked one other question about the- Mm-hmm. -the trial. So we are intending for this trial to be an open label study. As I think we all understand that with the route of administration for IMNN-001 being through a catheter, you know, directly into the microtumor environment, this is really an more of an ethical decision that the only way that you could preserve blind would be to to require for the control arm to also have that, which would be an unnecessary surgical procedure. So we are intending that there will be full agreement with FDA that this will be open label. And we'll certainly get buy-in on plans for event-driven endpoints and the ability to report out appropriately in the trial. I think she was talking about the COVID vaccine. Yeah. Sorry. Okay. Apologize. I misunderstood. Yeah. So you're gonna batch the, results, right? So for the IMNN-10 1? Yeah. That was your question? Oh, I apologize. Oh, yeah. Three. So, it is an open label trial. We are with this trial, really, you know, we do have part of what will be very exciting and interesting are the immunogenicity data that we expect to have by the end of the year. So we, of course, can do them in batches, but really, we're expecting to have the full sample from the trial, and to be able to to report out, you know, based on the the effects that we're seeing, and which really will establish proof of concept and will set up the the partnership discussions full, full stop. In the meantime, the DSMB is evaluating for safety? That's right. So we have, we have an ongoing, as you would expect in a phase 1 trial, you know, where you're needing to have, regular and planned DSMB reviews that trigger the release of additional patients, being treated. We've gone through multiple DSMB reviews of our data, seamlessly getting approval to continue, and, the study is enrolling exactly per the plan, so it's, it's, it's moving very, very well, very efficiently. Okay, great. Thanks for all the caller. I appreciate you taking the question. Thank you, Emily. Our next question comes from Kemp Dolliver from Brookline Capital Markets. Please go ahead with your question. And Kemp, is it possible that your phone is on mute? Okay, sorry. ... So thank you for taking the question. Just quickly on IMNN-101, when you say the study is enrolling exactly to plan, you know, COVID waves are not what they were a couple of years ago. So are you seeing steady enrollment, or is this a case where, as we get into the fall, you know, with this potential spike in COVID, you'll see a similar spike in enrollment? Yeah, so this, you know, this study is enrolling healthy, healthy subjects. We have a very experienced center that's running it. Per the numbers I've reviewed, and I look at them quite regularly, we're, you know, we're about 70%, above 70% of the patients that we will enroll in the trial, and they've been dosed. So I don't think I don't think the, you know, the, the, the flu season is likely to influence it. In fact, we expect really likely to be ahead of it in terms of completing, completing the trial and the observation. I'd like to comment on it also. So, I mean, there are a number of advantages that we believe will be demonstrated in this phase I study, not the least of which is durability. And of course, the handling characteristics allow this formulation to be managed at temperatures that are very friendly for a global distribution. That said, there may be an opportunity to replace mRNA vaccines, like, depending upon the data, that would be as boosters. As you point out, the market is waning some, but I think the more important outcome from this study is the proof of concept that a DNA vaccine can provide in other indications. And you may wanna speak to that. Yeah, I would- I'd love to add to that. I mean, I do think that, you know, we were very thoughtful in choosing the, what we would study to establish proof of concept of our technology. But as you guys are likely quite aware, there have been more than 80 pathogenic viruses discovered since 1980. The target of choice would really need to be decided in conjunction with, you know, the party who's going to develop it. We think there is enormous value to the technology, that we wanna make sure we maximize through a partnership. And, you know, there's equally exciting when we think about our core and our strategy down the path. There's even a potential, you know, for an oncology vaccine. So the platform itself, the technology is a very, very exciting for many reasons. Thanks for the question, Kemp. Sure, thanks, and also for the clarification. And then on IMNN-001 and the end of phase II process, you know, where does that stand? Are you in a position that you have been able to request a meeting? You know, and if not, when do you anticipate it? Because it strikes me that, given your expected timing for presenting the full data set and having clarity around the phase III trial design, you know, you can dovetail those two events together. You're going to have a lot more certainty in the eyes of potential partners and investors. Yeah, it's a great question, and we are expecting to be able to present the entire, the full data set at a, you know, major stage in the fall. Which we certainly will announce as soon as we have those plans. We are, as I shared in our, my prepared remarks, we're within days of requesting the end of phase II meeting. And, you know, as we look at ultimately, you know, our goal, which we are very much in line with in terms of all the steps that really lead up to first patient dose and kicking the study off, everything will align extremely well with doing that in Q1. You know, I do expect there will be many synergies around some of the catalysts you're describing and as well as others. Great, thank you. Our next question comes from David Bautz from Zacks. Please go ahead with your question. Hey, good morning, everyone. So Stacy, I was wondering if you could talk about maybe what are some of the most important design factors for the phase III trial that you're, that you're hoping to come into alignment with the FDA during your upcoming meeting? Yeah, Dave, David, that's a great question. And we are looking forward to certainly motivating what we believe is really a very strong design that, you know, we're coming to the table with input from leading clinicians that have been not only treating with IMUNON but, you know, dedicated their careers to women with ovarian cancer. You know, coming out of the OVATION 2 study, we certainly see this tantalizing synergistic effect, potential synergistic effect with PARP inhibitors. So one of the aspects that we're thinking very carefully about is ensuring that there's balance across the treatment arms in women that have genetic mutations that, you know, may predispose a strong response. You know, in the likely nature of, you know, with BRCA mutations, for example, HR deficiency, a very likely treatment with PARP inhibitors. So, certainly we want to make sure that we can answer key questions clearly. A nd bring evidence of, you know, of a very strong treatment effect then across the entire study, in addition to these key subgroups. So, the primary endpoint, I think, will be very straightforward. We're choosing the definitive endpoint. We expect that will be a very smooth discussion. So those are the overall survival is primary. The list of endpoints really, which are giving confidence and consistency in the data, which we're seeing very clearly in OVATION 2. Key factors that we're including into the design and, and then the establishment of the inclusion criteria, which really will set us up for a first-line indication statement. Those are the key things top of mind. Okay, great. Now, in regards to the MRD study, are you pleased with how enrollment is going? Is there anything maybe that can be done to kind of speed up enrollment in that study? Yeah, it's a great question. I was reviewing the system yesterday with our team, is doing a phenomenal job, you know, of managing the study internally. It turns out that the rate of enrollment is actually competitive. It's even higher than in OVATION 2. But we had and we have 7 patients treated right now out of 50. What needs to happen, so while MD Anderson has done phenomenally, we have 2 more sites. So Memorial Sloan Kettering is now on board. Johns Hopkins will be anticipated soon. So I think we can expect to see enrollment increasing as these sites now come into the fold and are meeting with patients and entering them into the study. You know, I think in terms of what we'll do, we'll certainly be meeting with each of the PIs, making sure that the data that has really very recently come out of OVATION 2 is at their fingertips, that they can describe, you know, to these women, that they're counseling of the potential of our product and are really armed with what they need to enroll patients that meet this inclusion criteria. But we are very pleased. Okay. To report some information at the end of the year, correct? That is correct. So, not only by the end of the year, but also Dr. Jazaeri, our PI, is interested and is planning on looking at some, you know, a pilot study of this. I talked about this a little bit in the opening remarks of circulating tumor DNA. Very interesting biomarker. He is, I think, worked a lot of very interesting translational biomarkers of the rich data that will come out of this study. So, instead of sitting and waiting passively, we're really looking at pilot studies, and then with second-look laparoscopy being the primary endpoint, we do expect to be able to release data on that endpoint before the end of the year. Okay, great. And just to clarify, so it sounds like if positive results for with IMNN-101, the company's gonna look to partner to advance that program. But is that to just advance the COVID program, or is it for the whole vaccine platform that you're gonna look to partner? Yeah, so we would look to partner the entire platform. Okay. We are very open. [crosstalk] All right, thanks. Mm-hmm. Yeah. Thank you. Great. Thanks for taking the question. Once again, if you would like to ask a question, please press star and one. To remove yourself from the question queue, you may press star and two. Our next question comes from James Molloy from Alliance Global Partners. Please go ahead with your question. Hey, guys. Thank you very much for taking my question. I had a question on the, on the PlaCCine program in general, and the preclinical development, PLX, X and Z 102, and you said you're looking to partner the whole thing. Would it be fair to say there's a sort of a shift in, or maybe a reshift back to the immunotherapy, rather than the PlaCCine DNA plasmid vector for the focus going forward? And could you walk through how the partnership environment currently looks for PlaCCine? And then perhaps as well, I imagine you're open to partnerships for the immunotherapy as well. Should this opportunity present, can you walk through how that partnership environment looks as well, please? Yeah, James, thanks for the question. You know, I, I think that, if I reflect back on my time on the board before joining as an employee and a CEO, you know, Imunon really has been a very highly focused company. And from a strategic perspective, we always looked at the PlaCCine platform as a wonderful offshoot of the, you know, our IL-12 technology, right? So it's an adaptation. We will continue to look for rich opportunities and the ability to bring transformative options into the marketplace. And then we'll also have to decide, what we choose to drive forward and what we can gain, in terms of furthering, you know, our business, non-dilutive funding for our core business, as well as, you know, really choosing strong partnerships. So I do think that, you know, for several years, we've been talking about the potential of this proof of concept study, but it really was for the technology, not truly launching into COVID-19. This was a vehicle to get us there, and I think that's something we wanted to really bring clarity to. So that is very much my intent coming in. In fact, you know, that resulted in really being very clear with our internal resources and ensuring we're allocating aligned with our priorities, and we very effectively been able to accomplish that, you know, in the last quarter. It may be premature to comment on partnerships, but I do think that, you know, Michael offered some remarks. You know, we are overwhelmed with the if you just compare to the current options, there are some strengths that we certainly have highlighted and will be very thrilled to highlight on future calls. But there is amazing potential, and I think it just needs to be in the right hands with the right motivation and focus. Great. Thank you for taking the questions. And with that, we'll be concluding today's question and answer session. I'd like to turn the floor back over to management for any closing remarks. Thank you, and really thank you to everyone for participating in this conference call. As our work in providing options to women with ovarian cancer progresses and the population's exposure to potential pandemics increases, we remain very excited about reporting data from ongoing clinical studies in the upcoming months. I also want to flag that, I'm being interviewed in a prerecorded fireside chat that will go live on 7:00 A.M., September 9, at the start of the H.C. Wainwright 26th Annual Global Investor Conference, which will be held in New York. We'll be putting that information out so you can view the conversation, and for those that are interested, we'll be available for one-on-one meetings at the conference and virtually. Contact H.C. Wainwright if you'd like a meeting. We look forward to keeping you informed of our progress and wish you a nice afternoon. Thanks for joining. Ladies and gentlemen, with that, we'll conclude today's presentation. We do thank you for joining. You may now disconnect.